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Abstract
Background: There is increasing evidence that elevated body mass index (BMI) is associ-
ated with reduced survival for women with breast cancer. However, the underlying rea-
sons remain unclear. We conducted a Mendelian randomization analysis to investigate a
possible causal role of BMI in survival from breast cancer.
Methods: We used individual-level data from six large breast cancer case-cohorts includ-
ing a total of 36 210 individuals (2475 events) of European ancestry. We created a BMI
genetic risk score (GRS) based on genotypes at 94 known BMI-associated genetic vari-
ants. Association between the BMI genetic score and breast cancer survival was ana-
lysed by Cox regression for each study separately. Study-specific hazard ratios were
pooled using fixed-effect meta-analysis.
Results: BMI genetic score was found to be associated with reduced breast cancer-specific
survival for estrogen receptor (ER)-positive cases [hazard ratio (HR)¼1.11, per one-unit incre-
ment of GRS, 95% confidence interval (CI) 1.01–1.22, P¼0.03). We observed no association
for ER-negative cases (HR¼1.00, per one-unit increment of GRS, 95% CI 0.89–1.13, P¼ 0.95).
Conclusions: Our findings suggest a causal effect of increased BMI on reduced breast
cancer survival for ER-positive breast cancer. There is no evidence of a causal effect of
higher BMI on survival for ER-negative breast cancer cases.
Key words: Body mass index, breast cancer survival, Mendelian randomization, epidemiology, genetics
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Introduction
Breast cancer is the most common form of cancer for
women worldwide.1 There is substantial variation in
survival outcomes between patients. Some of this vari-
ation can be explained by established clinico-pathological
factors including clinical stage, tumour grade and the
molecular phenotype of the tumour. However, other
factors such as germline genetic variation2 and lifestyle
factors may also be important. The association between
body mass index (BMI) and survival has been investigated
in many studies with increased BMI being associated with
a reduced survival,3–11 with some studies reporting an
association limited to estrogen receptor (ER)-positive dis-
ease.12–15 Whether this association is causal or simply
due to confounding by other factors remains unclear.
Mendelian randomization (MR)16,17 has become an estab-
lished method used to estimate the causal relationship be-
tween an exposure and an associated outcome using data on
inherited genetic variants that influence exposure status.
Genetic variants are attractive as candidate instrumental vari-
ables because they are randomly assigned at conception and
are not affected by potential environmental confounding fac-
tors. The use of germline genetic variants as instruments for
modifiable exposures has the potential to avoid some of the
limitations of conventional observational epidemiology for
making causal inferences.18 Recent genome-wide association
studies have identified multiple loci associated with BMI,19
enabling investigation of a possible causal role of BMI in
breast cancer outcomes using an MR approach.
The aim of this study was to utilize germline genotype
data for genetic variants known to be associated with BMI,
in a breast cancer case-cohort to evaluate the association
between BMI and breast cancer survival in an unbiased
way. There are three assumptions under which genetic
variants provide valid instrumental variables for the effect
of BMI on breast cancer survival: first, the genetic variants
are associated with BMI; second, the variants are not asso-
ciated with any confounder of the BMI-breast cancer sur-
vival association (pleiotropy); third, the variants are
conditionally independent of the survival, given the BMI
and confounders (exclusion restriction).
Methods
We included six datasets where a genotyping array provid-
ing genome-wide coverage of common genetic variation
had been used to genotype multiple breast cancer case-
cohorts in populations of European ancestry (COGS,
CGEMS, METABRIC, PG-SNPs, SASBAC and UK2).
A summary of these case-cohorts has been described in de-
tail previously.2 The characteristics of the studies used in
our analysis are summarized in Table S1 (available as
Supplementary data at IJE online). Genotypes for common
variants across the genome were imputed using a reference
panel from the 1000 Genomes Project (March 2012) for
each dataset. All patients provided written informed con-
sent, and each study was approved by the relevant institu-
tional review board. Data on age at diagnosis, vital status,
breast cancer-specific mortality, follow-up time, time be-
tween diagnosis and blood draw, lymph node status, histo-
logical grade, tumour size and estrogen receptor status
were also available. In addition, some case-cohorts from
the COGS study provided data on height and weight (self-
reported) at date closest to diagnosis (cases) or study entry
(controls) for 65 582 participants. BMI was calculated as
weight in kilograms divided by height in metres squared
(kg/m2).
Calculation of BMI genetic risk score
The Genetic Investigation of Anthropometric Traits
(GIANT) consortium involving over 300 000 individuals
of European descent has reported 97 common variants
associated with BMI, of which three were only associated
with BMI for men.19 We used the genotype data described
above to construct the BMI genetic risk score (GRS) based
on 94 BMI-associated genetic variants . The BMI genetic
risk score is given by the sum of the weighted imputed
allele doses (number of risk alleles carried) where the
weights are the reported beta-coefficients for association
with BMI. The manuscript19 presented the results as the
number of standard deviations increase in BMI per allele.
We therefore transformed these to the increase in BMI
per allele. The imputation r2 of all 94 single nucleotide
Key Messages
• Observational studies have reported an association between elevated body mass index (BMI) and reduced survival
for women with breast cancer. However, the causal nature of the association is unclear.
• We conducted a large Mendelian randomization analysis in order to examine a potential causal effect of BMI on
breast cancer survival, using both individual genotype data and summary data.
• Our study provides evidence that the reported association between BMI and survival for estrogen receptor-positive
breast cancer is likely to be causal.
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polymorphisms (SNPs) in the breast cancer dataset is
greater than 0.4.
Statistical analysis
We verified the first assumption of Mendelian randomization
by evaluating the association between BMI GRS and BMI in
a set of control subjects from the COGS study. MR analysis
was performed using Cox proportional hazard models, to
evaluate the associations of the BMI genetic risk scores with
breast cancer-specific mortality based on 36 210 cases with
2475 events over 170 504 person-years of follow-up. The
date of diagnosis was used to calculate time-to-event with
follow-up being censored at death, last follow-up or
10 years, whichever came sooner. As several studies
include prevalent cases, the date of study entry was used
to determine time under observation in order to adjust
for the potential bias of prevalent cases in a prospectively
recruiting study (left-truncation).20 All analyses were
performed for each study separately, and summary statis-
tics were obtained using a fixed-effect meta-analysis. We
also conducted MR subtype-specific analysis for 5683
ER-negative cases (679 events) and 22 567 ER-positive
cases (1161 events) (Table S1).
We assessed the relationship between BMI GRS and
breast cancer survival using summary statistics for the as-
sociation of each BMI- associated SNP with survival, for
each dataset. We used both an inverse-variance weighted
method and a likelihood-based method21 to estimate the
association. Several clinico-pathological factors are known
to be associated with survival. Rather than being true
potential confounders of any relationship between BMI
and survival, these factors should be considered as inter-
mediates. Nevertheless, in order to evaluate the second as-
sumption of MR, we tested for association between BMI-
associated SNPs and node status, tumour size and histolo-
gical grade. Alternatively, it is possible that smoking be-
haviour might mediate the true casual mechanisms for the
association between BMI and breast cancer survival. We
examined therefore the potential associations between
smoking behaviour (measured as self-reported total pack-
years smoked) and survival and between GRS and smok-
ing behaviour. Pleiotropic effects of the BMI SNPs on
unmeasured confounders may also violate the assump-
tion. The role of directional pleiotropy was assessed using
Egger regression on the summary statistics of association
for each BMI-associated SNP with survival.22 Egger
regression is a modified form of standard inverse-
variance weighted meta-analysis. When applied to MR
analyses, the slope of the Egger regression provides an
estimate of the causal effect, and the estimated value of
the intercept can be interpreted as an estimate of the
average pleiotropic effect across all the genetic variants.23
All analyses were performed using R (R project for
Statistical Computing).
Results
We observed strong positive associations between the BMI
GRS and observed BMI using a set of 28 190 controls from
the COGS study. A one-unit increase in GRS corresponds
to a 0.94 kg/m2 (95% CI 0.85–1.03, P¼ 4.16 1099) in-
crease in BMI and explained 1.6% of the BMI variance
(F statistic¼ 450). Self-reported BMI was significantly asso-
ciated with breast cancer survival for both ER-negative and
ER-positive disease in the COGS data (Table 1). Both asso-
ciations were attenuated after adjustment for tumour grade,
nodal status and tumour size.
We performed MR analysis for all available ER-
negative and ER-positive breast cancer cases. The GRS
Table 1. Association between BMI genetic risk score and survival for ER-positive and ER-negative breast cancer
ER-negative ER-positive
HR (95% CI) P HR (95%CI) P
Observational estimatea
Unadjusted 1.02 (1.01–1.04) 0.01 1.03 (1.02–1.04) 2.37105
Adjusted for nodes, size and grade 1.00 (0.97–1.02) 0.77 1.02 (1.00–1.05) 0.05
Individual-level data MR analysis
GRS 1.00 (0.89–1.13) 0.95 1.11 (1.01–1.22) 0.03
Summary results MR analysis
GRS IVWb 1.01 (0.91–1.12) 0.91 1.11 (1.01–1.21) 0.02
GRS likelihood-based 1.01 (0.91–1.12) 0.91 1.11 (1.02–1.21) 0.02
GRS Egger regression 0.91 (0.70–1.18) 0.46 1.11 (0.89–1.38) 0.36
aAssociation between self-reported BMI and survival (HR per unit increase in BMI).
bInverse-variance weighted.
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was found to be associated with reduced breast cancer-
specific survival for ER-positive cases with hazard ratio
(HR) of 1.11 (95% CI¼1.01–1.22, P¼ 0.03) per one-unit
increment of the GRS (Table 1). In order to evaluate
whether this association varied by menopausal status, we
compared the estimates for GRS for premenopausal
(defined as age at diagnosis< 50 years) and postmeno-
pausal (age at diagnosis 50 years) women with ER-
positive breast cancer, using data from the COGS study.
We found no evidence for a difference in the hazard ratios
(P¼ 0.93).
No significant association with genetic score was
observed for ER-negative cases (HR¼ 1.00, 95% CI 0.89–
1.13; Table 1). This indicates that the observed association
between BMI and breast cancer survival for ER-negative
cases might not be causal. However, we had only 38%
power to detect the same magnitude of association as that
observed for ER-positive disease with a type I error of
5%.24 The number of events would need to be approxi-
mately 2000 for a power of 80% in ER-negative cases
(Supplementary Figure 1, available as Supplementary data
at IJE online). The differences between the estimated asso-
ciations with genetic score for ER-positive and ER-
negative were not significant (P¼0.07). The association
between BMI and breast cancer survival was also evaluated
using standard inverse-variance weighted meta-analysis of
summary statistics for the association of each BMI-
associated SNP with survival. The results were similar to
those based on individual-level data (Table 1).
In order to test the validity of the exclusion restriction
assumption, we compared the results of a standard inverse-
variance weighted regression with the Egger regression for
the SNPs in the GRS (Figure 1A). The slope of the inverse-
variance weighted regression was 0.10 (95% CI 0.02–
0.19) which was similar to that from the Egger regression
0.10 (95% CI 0.11–0.32). The intercept from the Egger re-
gression was not significantly different from zero
(0.0002, P-value¼ 0.99), suggesting no overall direc-
tional pleiotropy. A funnel plot of the minor allele
frequency-corrected genetic associations with the BMI
against the individual causal effect estimates for each SNP
shows little evidence for asymmetry (Figure 1B).
We tested each GRS SNP for association with either
node status or grade or tumour size or stage. Sixteen of the
BMI SNPs were associated with one or more of these vari-
ables. We then repeated the individual data MR analysis
using a GRS-78 that excluded these SNPs. The magnitudes
of the associations with ER-positive breast cancer were
similar to those for the results based on all the BMI SNPs
(GRS-78: HR¼ 1.10, 95% CI 1.00–1.22, P¼ 0.06).
We explored a potential complex relationship between
smoking behaviour, BMI and prognosis by investigating
the association between BMI GRS and smoking behaviour
and between smoking behaviour and prognosis. There was
a very weak correlation between GRS and number of
pack-years smoked (correlation coefficient¼ 0.017,
P¼ 0.004). However, there was no association between
smoking and prognosis (P¼ 0.47 and 0.79 for ER-positive
Figure 1. Genetic associations of BMI GRS and breast cancer survival for ER-positive cases. (A) Scatter plot of log hazard ratio of genetic associations
with breast cancer survival for ER-positive cases against log odds ratio of association with BMI. Slope of the regression lines: inverse variance-
weighted (dotted) and MR-Egger (dashed) provide an estimate of the predicted log hazard ratio per unit increase in BMI. (B) Funnel plot of minor al-
lele frequency (MAF)-corrected log odds ratio of genetic associations with BMI against log hazard ratio per predicted unit increase in BMI on breast
cancer survival for each genetic variant individually.
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and ER-negative disease, respectively). It is unlikely that
the association between smoking behaviour and BMI can
explain the association between BMI GRS and prognosis.
Discussion
We conducted a large Mendelian randomization analysis
in order to examine a potential causal effect of BMI on
breast cancer survival, using both individual data and sum-
mary data. We constructed a weighted BMI genetic score
comprising 94 BMI-associated genetic variants identified
in genome-wide association studies as instrumental vari-
ables. We also used an inverse-variance weighted method
and likelihood-based method to evaluate the combined as-
sociation of BMI-associated SNPs with breast cancer sur-
vival. The results from the summarized data were in
agreement with the results from two-stage regression based
on individual-level genotype data. Our findings suggest a
possible causal association between increased BMI and
reduced breast cancer survival for ER-positive cases. This
provides consistent evidence, along with other findings,
that increased BMI has been repeatedly associated with
ER-positive breast cancer.
A limitation of the analysis is that, even if the genetic
variants are not associated with confounders of the rela-
tionship between BMI and breast cancer survival for the
population as a whole (that is, the genetic variants are
valid instrumental variables for the population), the gen-
etic variants may be associated with these confounders for
the subpopulation of breast cancer patients. This is due to
conditioning on a collider: if BMI is a causal risk factor for
breast cancer risk, then conditioning on breast cancer risk
(by only including breast cancer patients in the analysis)
means that all common causes of breast cancer risk
(including the genetic variants and confounders) are condi-
tionally associated. In simple terms, even if genetic variants
are distributed randomly in the population as a whole,
they are not necessary randomly distributed in the ascer-
tained population of breast cancer patients. This may lead
to bias in the analysis, although it is unclear how serious
this bias might be. In order to evaluate the potential for
collider bias, we performed a simulation study in which we
simulated data on a genetic risk score and an exposure
(BMI in our example) for 100 000 individuals. For each in-
dividual, we simulated whether that individual had a posi-
tive breast cancer diagnosis as a binomial random variable.
For each individual with a positive breast cancer diagnosis,
we simulated the time-to-event for breast cancer progres-
sion as an exponential random variable. The genetic risk
score was simulated as a normally distributed random vari-
able, as was the confounder (assumed unmeasured), and
the independent error term. The probability of breast
cancer diagnosis was modelled as a function of the expos-
ure. This leads to the collider (selection) bias: individuals
with a breast cancer diagnosis (and therefore eligible for
the Mendelian randomization analysis) will have higher
average levels of the exposure and confounder than those
not included. While collider bias was observed for extreme
values of the effect of the risk factor on disease status, it
was not observed for values that are in line with the effect
of BMI on breast cancer diagnosis as observed in previous
investigations. Hence, while we would be cautious not to
generalize the result of this limited simulation study to
other analysis contexts, in this case there seemed to be little
potential for bias and type 1 error rate inflation to arise
due to collider bias.
While our results suggest a causal association between
BMI and survival for women with ER-positive breast can-
cer, BMI is, in itself, a complex phenotype. It is conceivable
that more specific phenotypes related to body fat compos-
ition and distribution might be better predictors of out-
come. Untangling such complex relationships with survival
will require data on the association between germline gen-
etic variation and specific body fat composition and distri-
bution phenotypes. Potential mechanisms underlying
effects of obesity on breast cancer survival are mediators
such as members of the insulin/insulin-like growth factor
family, adipocytokines secreted from adipose tissue and in-
flammatory cytokines.23
Our study, based on data from multiple large-scale
genetic association studies of breast cancer, provides
evidence that the reported association between BMI and
survival for ER-positive breast cancer is likely to be
causal. This suggests that BMI reduction in overweight
women with ER-positive breast cancer might improve
clinical outcomes.
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